KyungDong Pharm home
Prescription Medicines

Uroscan Tab.

Product Category
Benign prostatic hyperplasia treatment
Active Ingredients
finasteride
Appearance
Blue round film-coated tablet
Reimbursement Code
648101670
View Regulatory Information on the MFDS Portal ↗
1. Composition and Strength
1 tablet
- Active ingredient: Finasteride (USP)----5mg
- Additive (tar color aluminum lake): Blue No. 2
- Additives (animal-derived ingredients): Magnesium stearate (beef, beef tallow, pork, pork), lactose hydration
Water (cow, milk)
- Other additives: light anhydrous silicic acid, microcrystalline cellulose, titanium oxide, pregelatinized starch, cloth
Povidone, talc, polyethylene glycol 6000, floxamer 407, hydroxypropyl cellulose, hypromellose 2910

2. Effectiveness
Benign Prostatic Hyperplasia:
- Improvement of benign prostatic hyperplasia symptoms
- Degeneration of enlarged prostate and improvement of urinary flow
- Reduced incidence of acute urinary retention
- Reduced need for surgery, including transurethral resection of the prostate and prostatectomy surgery

3. Dosage and dosage
Finasteride is administered orally at 5 mg once a day, regardless of meal.
- Even if symptoms improve when taking the drug, treatment for at least 6 months is required.
- Patients with renal failure: From a pharmacokinetic perspective, there was no change when administering this drug, so there is no need to adjust the dose for patients with various types of renal failure (creatinine clearance: 9.0 mL/min).
- Elderly: Although the excretion of this drug is slightly reduced in elderly people over 70 years of age, there is no need to adjust the dose.

4. Precautions for use
1. Warning
1) This drug should not be administered to children or women.
2) Pregnant women or women who may become pregnant should not touch broken or broken pieces of finasteride due to the possibility of absorption of finasteride and subsequent potential risk to the male fetus. Because the drug is coated, normal handling prevents contact with the active ingredient unless broken or broken.
3) Mood swings and depression
Depressed mood and depression were reported in patients administered 5 mg of finasteride, and in smaller cases, mood swings including suicidal thoughts were reported. Patients should be monitored for psychiatric symptoms and should be consulted by a medical professional if these symptoms occur.

2. Do not administer to the following patients.
1) Patients with hypersensitivity to this drug or its components
2) Women or children
3) Women who are pregnant or may be pregnant
4) Since this drug contains lactose, it should not be administered to patients with genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.

3. Administer with caution to the following patients.
Patients with abnormal liver function

4. Adverse reactions
1) This drug was well tolerated and adverse reactions were generally mild and transient.
2) Foreign clinical trials
In a 4-year placebo-controlled clinical trial (PLESS, Proscar Long-Term Efficacy and Safety Study), a 4-year safety evaluation was conducted on 1,524 patients treated with this drug and 1,516 patients treated with placebo. 3.7% (57 patients) treated with this drug and 2.1% (32 patients) treated with placebo discontinued treatment due to adverse reactions related to sexual function. The most frequently reported adverse reactions were adverse reactions related to sexual function. Adverse reactions that occurred at a higher frequency than placebo in the 4-year clinical trial, had an incidence rate of more than 1% with this drug, and were considered possibly, possibly related, or definitely related to the drug by the clinical trial investigators are shown in Table 1 below. There was no significant difference in the rates of erectile dysfunction, decreased libido, and ejaculatory disorders between treatment groups in the 2 to 4 year clinical trial.

Table 1. Drug-related adverse reactions
(Please refer to the attached document for further details)

3) Data on long-term use
In a placebo and positive control clinical trial conducted on 3,047 patients for 4 to 6 years, 4 cases of breast cancer occurred in the group administered 5 mg of this drug, and no cases occurred in the placebo group or positive control group. In a separate placebo-controlled clinical trial conducted for 4 years on 3,040 patients, 2 cases of breast cancer occurred in the placebo group and no cases occurred in the 5 mg treatment group. In a 7-year placebo-controlled clinical trial (Prostate Cancer Prevention Trial, PCPT) in which 18,882 men participated, one case of breast cancer occurred in each of the drug-treated and placebo groups. There are post-marketing reports of male breast cancer. The relationship between long-term administration of this drug and male breast neoplasms is currently unknown.
The PCPT clinical trial was a 7-year, randomized, double-blind, placebo-controlled clinical trial involving 18,882 men aged 55 years or older with normal digital rectal examination and prostate specific antigen (PSA) levels ≤3.0 ng/mL. Men received 5 mg of this drug or placebo once daily. Patients were evaluated for digital rectal examination and PSA every year, and biopsies were performed when PSA was elevated or the digital rectal examination was abnormal, and at the end of the clinical trial. The incidence of Gleason grade 8 to 10 prostate cancer was higher in men receiving this drug (1.8%) compared to men receiving placebo (1.1%). In a 4-year placebo-controlled clinical trial of another 5α-reductase inhibitor (dutasteride), similar results were observed for Gleason grade 8 to 10 prostate cancer (1% dutasteride vs. 0.5% placebo). Clinical benefit in patients with prostate cancer receiving 5 mg of this drug has not been proven.
4) Foreign post-marketing surveillance
The following adverse reactions have been additionally reported with this drug and/or at low doses of this drug. Because these adverse reactions are voluntarily reported from an unspecified population, it is generally not possible to reliably estimate their incidence or establish a causal relationship with drug exposure.
(1) Immune system: Hypersensitivity reactions such as itching, hives, and angioedema (including swelling of the lips, tongue, throat, and face)
(2) Musculoskeletal and connective tissue disorders: muscle pain, myasthenia gravis
(3) Mental system: depression, suicidal thoughts, decreased libido that persists after discontinuation of administration, anxiety
(4) Reproductive system and breast: testicular pain; Hematospermia: Sexual dysfunction (erectile dysfunction, ejaculation disorder) that persists after discontinuation of administration; Male infertility and/or poor semen quality. Normalization or improvement in semen quality has been reported after discontinuation of finasteride administration. ; male breast cancer
(5) Gastrointestinal disorders (heartburn), dizziness, headache
5) Domestic post-marketing surveillance
As a result of a post-marketing survey conducted on 3,675 people over 6 years, the incidence of adverse reactions was 124 cases (3.37%) in 107 people, regardless of causal relationship. Among these, those evaluated as having a causal relationship with this drug were gastrointestinal disorders (heartburn), erectile dysfunction, decreased libido, ejaculatory disorders (reduced semen volume), rash, itching, hypersensitivity, headache, and dizziness.
(1) Digestive system: 7 cases (0.19%) including indigestion, constipation, gastrointestinal disorder (heartburn), thirst, etc.
(2) Urogenital system: 102 cases (2.78%) including erectile dysfunction, decreased libido, ejaculation disorder (reduced semen volume), etc.
(3) Skin: rash, itching, etc. 2 cases (0.05%)
(4) Whole body: Numbness in both hands, hypersensitivity, headache, malaise, etc. 6 cases (0.16%)
(5) Others: 7 cases (0.19%), including dizziness, otitis media, liver function abnormalities, etc.

5. General precautions
1) Since the efficacy of this drug is not immediately apparent, patients with a large amount of residual urine or patients with severely reduced urinary flow should be carefully examined for obstructive urinary tract diseases.
2) Before starting treatment with this drug, doctors must conduct an appropriate evaluation to check for infections, prostate cancer, stenotic disease, storage bladder, or other neurological diseases similar to benign prostatic hyperplasia (BPH). Instruct patients to read the product instructions and read it again each time the prescription is renewed, so that patients are aware of the latest information related to this drug.
3) Doctors should inform patients that ejaculate fluid may decrease in some patients during treatment with this drug. Although this reduction in ejaculate fluid does not appear to interfere with normal sexual function, erectile dysfunction and decreased libido may occur in patients treated with this drug.
4) In a PCPT clinical trial targeting men aged 55 years or older with a normal digital rectal examination and PSA level ≤ 3.0 ng/mL, who took 5 mg of this drug daily for 7 years, the risk of Gleason grade 8 to 10 prostate cancer was increased (finasteride 1.8% vs. placebo 1.1%).
Similar results were observed in a 4-year placebo-controlled clinical trial of another 5α-reductase inhibitor (dutasteride) (1% dutasteride vs. 0.5% placebo). 5α-reductase inhibitors may increase the risk of developing high-grade prostate cancer, but it has not been established whether this is due to the effect of 5α-reductase inhibitors to reduce prostate volume or other factors that influence the results of these studies.

6. Interaction
1) There are no known drug interactions related to this drug.
2) This drug does not affect the CYP-450 related drug metabolizing enzyme system, so it does not interact with drugs metabolized by this mechanism, such as propranolol, digoxin, glybrid, warfarin, theophylline, and antipyrine.
3) No clinically significant adverse reactions occur when administered in combination with ACE inhibitors, alpha blockers, beta blockers, calcium channel blockers, cardiac nitrate agents, diuretics, H2 antagonists, HMG CoA reductase inhibitors, non-steroidal anti-inflammatory drugs (NSAIDS), quinolones, benzodiazepines, etc.

7. Administration to pregnant and lactating women
1) This drug is prohibited to be administered to pregnant women or women who may be pregnant. If a pregnant woman takes this drug, it may cause abnormalities in the external genitalia of the male fetus (type II 5α-reductase inhibitors inhibit the conversion of testosterone to dihydrotestosterone). If you take this drug during pregnancy or become pregnant while taking this drug, the pregnant woman should be informed of the potential risk to the male fetus. In animal experiments on female rats, low doses of this drug administered during pregnancy resulted in vulvar deformities in male pups.
2) Broken pieces of this medicine should not be handled by pregnant women or women who may be pregnant, as the broken pieces of this medicine may be absorbed and cause abnormalities in the external genitalia of the pregnant male fetus. However, if this medicine is not broken or broken, it is coated and is not exposed to the active ingredient during normal handling.
3) In clinical trials, a small amount of finasteride was recovered from the semen of subjects who took 5 mg/day of this drug for 6 to 24 weeks. The concentration of finasteride that pregnant women are exposed to through the semen of patients treated with this drug is 50 to 100 times lower than the concentration of finasteride corresponding to the no-effect level for fetal development abnormalities reported in animal experiments with rhesus monkeys.
4) It is unclear whether this drug passes into breast milk and should not be administered to nursing mothers.

8. Administration to children
It cannot be administered to children because its safety and effectiveness in children have not been established.

9. Administration to elderly people
Among the subjects who participated in the foreign placebo-controlled clinical trial (PLESS), 1,480 were over 65 years of age and 105 were over 75 years of age. No significant differences in safety and efficacy were observed between older and younger subjects, and other clinical experience showed no differences in response between older and younger patients. No dose adjustment is necessary for elderly people.

10. Effect on clinical test values
1) Clinical efficacy has not been proven in prostate cancer patients treated with this drug. In a controlled clinical trial, patients with benign prostatic hyperplasia with elevated PSA were monitored by serial prostate-specific antigen (PSA) levels and prostate biopsies. In these BPH clinical trials, this drug did not appear to change the rate of prostate cancer diagnosis. Additionally, the overall incidence of prostate cancer was not significantly different in patients treated with this drug or placebo.
This drug reduces the serum PSA concentration of patients with benign prostatic hyperplasia by approximately 50%, even in the presence of prostate cancer. This decline is predictable across the entire range of PSA levels, although it varies depending on the individual patient. An analysis of PSA data from more than 3,000 patients in the PLESS clinical trial confirmed that the PSA level of a typical patient treated with this drug for more than 6 months should be doubled compared to the normal range for untreated men. This adjustment preserves the sensitivity and specificity of the PSA analysis and maintains the ability to diagnose prostate cancer.
Sustained increases in PSA levels in patients treated with this drug should be carefully evaluated, including consideration of issues of nonadherence to treatment with this drug.
Percent free PSA levels (the ratio of free PSA to total PSA) are not significantly reduced by this drug. The ratio of free PSA to total PSA remains the same under the influence of this drug. If the percentage free PSA level is used as an aid in diagnosing prostate cancer, no adjustment to this value is necessary.
2) In patients with benign prostatic hyperplasia, this drug did not affect circulating levels of cortisol, estradiol, prolactin, thyroid-stimulating hormone, or thyroxine. No clinically significant drug effects were observed on plasma lipid profile (i.e. total cholesterol, low-density lipoprotein, high-density lipoprotein, triglycerides) or bone mineral density. In patients taking this drug, an increase of approximately 10% in luteinizing hormone (LH) and follicle-stimulating hormone (FSH) was observed, but the levels were within the normal range. In healthy volunteers, treatment with this drug does not alter the response of LH and FSH to gonadotropin-releasing factor, suggesting that the hypothalamic-pituitary-testicular axis is not affected.
To assess semen parameters in healthy male volunteers, 24 weeks of treatment with this drug did not have clinically significant effects on semen concentration, motility, morphology, or pH. The total semen volume decreased during ejaculation, and a decrease in average ejaculate volume of 0.6 mL (22.1%) was observed. These parameters were within the normal range and began to disappear when treatment was discontinued, returning to baseline after an average of 84 weeks.

11. Treatment in case of overdose
1) There is no specific treatment recommended for overdose of this drug.
2) No adverse reactions occurred in patients who took single doses of up to 400 mg of this drug or repeated doses of up to 80 mg per day for 3 months.

12. Precautions for storage and handling
1) Keep out of reach of children.
2) Be careful because changing it into another container may cause an accident or is undesirable in terms of maintaining quality.

5. How to save
Store at room temperature (1~30℃), light-proof, airtight container

6. Packaging unit
30 tablets (10 tablets/PTP

7. Expiration date
36 months from date of manufacture

Product Updates

Total 9items

No.Product NameDetailsDate of ChangeDownload
9Uroscan Tab.Precautions for use2024.10.30PDF20_200501987_Euroscan tablet_Precautions for use (draft change).pdf
8Uroscan Tab.Precautions for use2021.02.16HWPContents of permission change order_finasteride_tablet_5mg.hwp
7Uroscan Tab.Precautions for use2019.04.03PDF0069_200501987_Precautions for use (Euroscan tablet).pdf
6Uroscan Tab.Precautions for use2018.09.05PDF0097_200501987_Precautions for use_Euroscan Tablet.pdf
5Uroscan Tab.Euroscan Tablet (Precautions for use)2017.08.22HWPChanges_Euroscanjeong.hwp
4Uroscan Tab.Euroscan tablet (efficacy, dosage, usage, precautions...2013.12.30HWP2012 Pharmaceutical Literature Re-evaluation (Euroscan Tablet).hwp
3Uroscan Tab.Euroscan Tablet (Precautions for use)2012.09.12HWPPrecautions for using Euroscan tablets.hwp
2Uroscan Tab.Euroscan Tablet (Precautions for use)2009.10.07HWPChange in Euroscan tablets (precautions for use) (2009.10.12).hwp
1Uroscan Tab.Euroscan Tablet (Precautions for use)2006.11.22HWPEuroscan tablet (precautions for use) change (2006.12.04).hwp